Next Article in Journal
K+···Cπ and K+···F Non-Covalent Interactions in π-Functionalized Potassium Fluoroalkoxides
Next Article in Special Issue
Synthesis and In Vitro (Anticancer) Evaluation of η6-Arene Ruthenium Complexes Bearing Stannyl Ligands
Previous Article in Journal
Structural Study of Mismatched Disila-Crown Ether Complexes
Previous Article in Special Issue
Anticancer Applications and Recent Investigations of Metallodrugs Based on Gallium, Tin and Titanium
 
 
Article

A Cancer Stem Cell Potent Cobalt(III)–Cyclam Complex Bearing Two Tolfenamic Acid Moieties

Department of Chemistry, King’s College London, London SE1 1DB, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Luigi Messori
Inorganics 2017, 5(1), 12; https://doi.org/10.3390/inorganics5010012
Received: 19 December 2016 / Revised: 17 January 2017 / Accepted: 25 January 2017 / Published: 9 February 2017
(This article belongs to the Special Issue Tumor Inhibiting Metal Complexes)
Cancer stem cells (CSCs) are thought to be responsible for cancer relapse. CSCs are a subtype of cancer cells with the ability to differentiate, self-renew, and form secondary or tertiary tumors. Current cancer treatments—including chemotherapy, radiation, and surgery—effectively remove bulk cancer cells but are unable to eliminate CSCs. Here, we present the synthesis, characterization, and anti-CSC properties of a cobalt(III)–cyclam complex bearing two tolfenamic acid moieties, 3. Notably, 3 displays sub-micromolar potency towards breast CSCs and bulk breast cancer cells. Detailed mechanistic studies show that 3 is taken up readily by breast CSCs, enters the nucleus, causes DNA damage, and induces caspase-dependent apoptosis. Furthermore, 3 inhibits cyclooxygenase-2 (COX-2) expression in CSCs. The mechanism of action of 3 is similar to that of a naproxen-appended cobalt(III)–cyclam complex, 1 recently reported by our group. The advantage of 3 over 1 is that it has the potential to remove whole tumor populations (bulk cancer cells and CSCs) with a single dose. View Full-Text
Keywords: metallopharmaceuticals; cobalt(III)–cyclam complexes; cancer stem cell; nonsteroidal anti-inflammatory drug; DNA damage; COX-2 inhibition metallopharmaceuticals; cobalt(III)–cyclam complexes; cancer stem cell; nonsteroidal anti-inflammatory drug; DNA damage; COX-2 inhibition
Show Figures

Graphical abstract

MDPI and ACS Style

Cressey, P.B.; Eskandari, A.; Suntharalingam, K. A Cancer Stem Cell Potent Cobalt(III)–Cyclam Complex Bearing Two Tolfenamic Acid Moieties. Inorganics 2017, 5, 12. https://doi.org/10.3390/inorganics5010012

AMA Style

Cressey PB, Eskandari A, Suntharalingam K. A Cancer Stem Cell Potent Cobalt(III)–Cyclam Complex Bearing Two Tolfenamic Acid Moieties. Inorganics. 2017; 5(1):12. https://doi.org/10.3390/inorganics5010012

Chicago/Turabian Style

Cressey, Paul B., Arvin Eskandari, and Kogularamanan Suntharalingam. 2017. "A Cancer Stem Cell Potent Cobalt(III)–Cyclam Complex Bearing Two Tolfenamic Acid Moieties" Inorganics 5, no. 1: 12. https://doi.org/10.3390/inorganics5010012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop